A Phase I Dose Defining Study For MK-2206 Combined With Gefitinib In NSCLC Population Enriched With EGFR Mutation.
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2015
At a glance
- Drugs MK 2206 (Primary) ; Gefitinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 26 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Nov 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 26 Nov 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.